Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with chemoradiation in locally advanced cervical cancer
NCT03298893Phase 2Completed
- Sponsor
- Institut Curie
- Start
- Nov 2017
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in Cervical Cancer (CC), sponsored by Institut Curie. Started Nov 2017; status: completed.
02
Drugs
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03298893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03298893.